Latest From Osivax
Emerging Company Profile: Osivax is using its oligoDOM technology platform to developer a vaccine pipeline. The French biotech aims to establish proof-of-concept in influenza A then expand the pipeline to provide a universal flu vaccine.
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Company Type
- Parent & Subsidiaries
- Senior Management
Alexandre LeVert, CEO
Fergal Hill, PhD, CSO
Paul Willems, MD, CMO
Delphine Delphine GUYON-GELLIN, Chief Bus. Dev. Officer
- Contact Info
Phone: 4 37 65 55 03
99, rue de Gerland
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.